GIGilead Sciences GILD NASDAQ · Healthcare · United States
$166.43 -0.06% -$0.10
- Market cap
- $206.6B
- Enterprise value
- $226.3B
- P/E
- -
- Forward P/E
- -
- PEG
- 0.0x
- P/S
- 6.7x
- P/FCF
- 15.0x
- EV/EBITDA
- 175.2x
- ROIC
- 42.7%
- Gross margin
- 79.9%
- Net margin
- -12.5%
- Dividend yield
- 1.95%
- Payout ratio
- -
- Net debt/EBITDA
- 15.3x
- Beta
- 0.37
- Free float
- 99.8%
About the company
Gilead Sciences, Inc. (GILD) is an American biopharmaceutical company specializing in research, development, and manufacturing of pharmaceuticals in the field of infectious diseases, viral diseases, and chronic conditions, such as HIV/AIDS, hepatitis C, hepatitis B, and more. The company is renowned for its innovative treatment approaches and drugs that have a significant impact on improving the quality of life for patients worldwide. Gilead Sciences is actively engaged in research and collaborates with academic institutions and healthcare organizations to discover new therapies and medications. With successful products and a strong research background, Gilead Sciences, Inc. has the potential for further innovations and expanding its pharmaceutical portfolio. Investing in Gilead Sciences, Inc. (GILD) shares may present an interesting choice for investors who follow the pharmaceutical sector and seek a company with a track record of successful products and commitment to combating serious diseases.
Sector
Healthcare
Industry
Drug Manufacturers - General
CEO
Daniel O'Day
Employees
17,000
Headquarters
Foster City
Valuation
Is today's price reasonable?
- What to watch: The share price is above the Bulios Fair Price.
Growth and estimates
Is it growing, and what comes next?
- What speaks for it: Earnings per share grew by 23% a year over the last 3 years.
- What to watch: Revenue grew by only 2.6% a year over the last 3 years.
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: It earns 43 USD a year on every 100 USD of invested capital.
- What speaks for it: Out of every 100 USD of revenue, 44 USD is left as free cash.
- What to watch: The company made a loss over the last 12 months.
Financial health
Can it carry its debt?
- What to watch: Repaying its net debt would take 15.3 years of operating profit.
Capital and dividends
What does the company do with the money it earns?
- What speaks for it: It has raised its dividend 10 years in a row.
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number